Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Read the entire article.
Click https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext link to open resource.